MyFinsight
Home
Blog
About
Maturity of
available-for-sale securities
$29,538K
(19.18%↑ Y/Y)
Net income
$8,189K
Accrued expenses and
other
$6,651K
Depreciation and
amortization
$2,516K
Stock-based compensation
$1,953K
Operating lease assets and
liabilities, net
-$300K
Net cash provided by
(used by) investing...
$7,972K
(182.04%↑ Y/Y)
Net cash provided by
operating activities
$1,624K
(-90.82%↓ Y/Y)
Canceled cashflow
$21,566K
Canceled cashflow
$17,985K
Net increase
(decrease) in cash, cash...
-$1,747K
(88.00%↑ Y/Y)
Canceled cashflow
$9,596K
Purchase of
available-for-sale securities
$21,566K
(-37.34%↓ Y/Y)
Accounts receivable, net
$7,731K
Accounts payable
-$5,061K
Inventory, net
$4,631K
Post-marketing commitment
liability
-$544K
Prepaid expenses and
other
$15K
Other current assets
$3K
Net cash used in
financing activities
-$11,343K
(49.66%↑ Y/Y)
Payment of debt
$11,120K
(-49.95%↓ Y/Y)
Payment of exit costs
$223K
(-49.77%↓ Y/Y)
Back
Back
Cash Flow
PUMA BIOTECHNOLOGY, INC. (PBYI)
PUMA BIOTECHNOLOGY, INC. (PBYI)
source: myfinsight.com